Even though discrepancies among myonectin and ERFE assays [4,12,20] still need to be understood and reconciled, it should be noted that other biomarkers that per sé underlie a protective action for the CV system, like adiponectin—a paralogue to ERFE—are directly, rather than inversely, related to the risk of death in HD patients [22]. This evidence concerns the gene ADIPOQ and Huntington disease.